1. DPYD Genotyping as a Potential Cost-effective Predictive Biomarker of Capecitabine Toxicity in Breast Cancer. Issue 6 (June 2015) Authors: De Souza, K.; Papadatos-Pastos, D.; Karapanagiotou, L.; Sandri, I.; Marinaki, A.; Mansi, J. Journal: Clinical oncology Issue: Volume 27:Issue 6(2015) Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pretreatment DPYD Genotyping Reduces the Risk of Capecitabine-associated Severe Toxicities: a Prospective Validation Study. Issue 7 (July 2019) Authors: Stavraka, C.; Pouptsis, A.; Okonta, L.; De Souza, K.; Marinaki, A.; Karapanagiotou, E.; Papadatos-Pastos, D.; Mansi, J. Journal: Clinical oncology Issue: Volume 31:Issue 7(2019) Page Start: e114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Issue 2 (17th December 2012) Authors: Smith, M.; Blaker, P.; Patel, C.; Marinaki, A.; Arenas, M.; Escuredo, E.; Anderson, S.; Irving, P.; Sanderson, J. Journal: International journal of clinical practice Issue: Volume 67:Issue 2(2013) Page Start: 161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗